



## Life Sciences

As the legal matters confronting our life science clients are varied, so are the skill sets we employ. DLA Piper's life sciences team comprises lawyers with legal, scientific and medical knowledge who understand the complexity of the business and regulatory environments in which our clients operate.

The challenges facing today's biotechnology and medical device companies are greater than ever. For companies to take promising therapies from the laboratory to the market, they must protect those therapies from IP, regulatory and reputational risks. Furthermore, the last few years have seen increasing pressure from many sides: demand for greater shareholder return, loss of key revenue streams due to patent expiration or generic challenges, fierce competition in key therapeutic areas, pricing pressures from health care payors, increased government regulation beyond core safety issues, rising costs of R&D, challenges in maximizing return in emerging markets and aggressive government enforcement action.

Our life sciences sector team is one of the largest and most active of any law firm. Operating as one team across more than 30 jurisdictions, we combine subject matter experience with considerable knowledge of the sector, including the scientific, medical, regulatory, commercial and enforcement environments facing our biopharmaceutical, medical device, research and diagnostics clients.

DLA Piper's team includes award-winning lawyers practicing litigation, compliance and investigations, IP strategy and enforcement, M&A, licensing and distribution and clinical trial advice. They also support clients across all other areas needed to address risk, including government affairs, environmental law, import/export, tax, real estate and employment law. Many of our lawyers are former sector professionals, many have PhDs or other advanced degrees in the life sciences field and others are former government officials or prosecutors.

Recognizing that our clients' needs vary, we rapidly organize and customize our client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company. These teams are supported by international and local practitioners to efficiently meet the demands of the matter.

Our cutting-edge staffing, budgeting and billing systems, created specifically to assist our global life science clients, ensure that our teams deliver value in addition to great results.

Our life sciences team helps clients solve their biggest challenges every day. Examples of our experience include:

- Conducting a sensitive investigation in China
- Negotiating a complex multi-country distribution deal in Latin America
- Acting as National Counsel on a mass tort in the US

### Marco de Morpurgo

Partner  
Rome  
T: +39 06 68 880 1  
[marco.demorpurgo@dlapiper.com](mailto:marco.demorpurgo@dlapiper.com)

### Andrew P. Gilbert

Partner  
New Jersey (Short Hills)  
T: +1 973 520 2553  
[andrew.gilbert@dlapiper.com](mailto:andrew.gilbert@dlapiper.com)

### Matt Holian

Partner  
Boston  
T: +1 617 406 6009  
[matt.holian@dlapiper.com](mailto:matt.holian@dlapiper.com)

- Antitrust and Competition
- Corporate
- Employment
- Intellectual Property and Technology
- International Tax Counsel
- Litigation, Arbitration and Investigations
- Real Estate
- Tax
- Corporate Disputes

- Helping sell or acquire a major business asset
- Advising on implementation of transparency laws or the impact of other new legislation
- Devising a risk mitigation plan for a key product
- Negotiating a large vaccine contract with a global NGO
- Counselling on a multi-jurisdictional clinical trial
- Advising on the downsizing of employees in Europe
- Supporting global business conduct and compliance functions
- Outsourcing critical R&D or IT functions
- Devising an IP strategy for a promising new therapy
- Negotiating a worldwide licensing and collaboration deal
- Protecting a blockbuster drug in patent litigation

## INSIGHTS

---

### Publications

#### Global M&A Intelligence Report 2022

3 May 2022

Our annual Global M&A Intelligence Report is based on an analysis of key deal terms in almost 5,000 private M&A transactions on which we have advised since 2015.

---

#### Life Sciences

29 April 2022

A brief description of key legislative changes in the health sector.

---

#### Israel Group News April 2022

28 April 2022

#### ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

#### US escalates its sanctions regime against Russia, targeting its financial system

28 February 2022

#### GLOBAL SANCTIONS ALERT

And additional measures are expected to be announced by the US and its allies in the coming days

---

#### Aiscension: an AI tool to ensure effective risk management by detecting anti-competitive practice

24 February 2022

Anti-competitive activity has been rife in companies for centuries and there are many who like to take the ostrich approach and bury their head in the sand. However, it is known that this approach to risk management is ineffective should the regulators come looking, and with fines of up to 10% of global turnover, it is a big risk to take.

---

## **New US sanctions in response to Russia's actions against Ukraine**

23 February 2022

### **GLOBAL SANCTIONS ALERT**

Additional sanctions are expected that will target Russia's financial, technology, and defense sectors.

---

## **Israel Group News January 2022**

24 January 2022

### **ISRAEL GROUP NEWS**

In this issue, our global activities, latest publications, recent events and more.

---

## **A legal overview**

4 January 2022

### **UNDERSTANDING THE UK NATIONAL SECURITY & INVESTMENT REGIME PODCAST**

In episode 2 of our podcast series we discuss the legal context of the regime: how it will operate and the implications for businesses. In particular, the legislation - which comes into force today, 4 January - has wide reaching implications for M&A involving businesses or assets connected with the UK.

---

## **Supporting the health of your health system: 2022**

3 January 2022

Helping you tend to healthcare system wellness throughout the business life cycle.

---

## **Global COVID-19 Vaccine Guide for Employers**

22 December 2021

*Updated on 21 January 2022*

As the scientific response to the COVID-19 pandemic develops, many employers are considering what their approach should be to the issues around vaccination for their workforce, with a view to accelerating a return to some kind of normality. This is an area where law, guidance and best practice is likely to develop rapidly and there is no one-size-fits-all solution, particularly for multinational employers. The risks, challenges and benefits will vary depending on the profile of the workforce and nature and location of the business.

In our newly launched global guide we set out some of the key considerations with regard to requiring or encouraging employees to be vaccinated and highlight some of the differences in risk around the world. These are complex and evolving issues and the situation should be kept under review as vaccine programmes become more widely available, economies and borders begin to open up again and more people return to the workplace.

---

## **Get ready for collective actions in Europe**

6 December 2021

Our client risk report "Get ready for collective actions in Europe", summarises the key trends and risks that consumer businesses in Europe may face following the Collective Redress Directive's implementation at the end of 2022.

---

---

## **The Industry Agreement on Chemical, Petrochemical, Biotechnological and Chemical-Pharmaceutical Organisations to be extended in Russia**

1 December 2021

On 11 November 2021, the Russian Ministry of Labour published in the Russian Gazette the Additional Agreement on the Prolongation for 2022-2024 of the Industry Agreement on Chemical, Petrochemical, Biotechnological and Chemical-Pharmaceutical Organisations (Agreement).

---

## **European Commission's Proposals for reform of AIFMD, UCITS Directive and the ELTIF regime**

26 November 2021

Following its review of the scope and functioning of the Alternative Investment Funds Manager Directive<sup>1</sup> (AIFMD), the European Commission (the Commission) has concluded that the AIFMD's standards for ensuring high levels of investor protection are mostly effective, but that amendments are required which are intended to be targeted in scope, but may have far-reaching effects.

The Commission has now published new legislative amendments to AIFMD, the UCITS Directive<sup>2</sup> (UCITSD) and the ELTIF Regulation<sup>3</sup> (ELTIF Regulation) (the Commission Proposal). The proposed amendments set out in the Commission Proposal will be introduced by way of an omnibus directive amending the AIFMD, UCITSD and the ELTIF Regulation.<sup>4</sup>

---

## **The Glasgow Climate Pact: What does it mean for Business?**

23 November 2021

In this article, members of our Sustainability and ESG Steering Committee share their thoughts on eight key themes emerging from COP26 and what they mean for business.

---

## **Israel Group News October 2021**

25 October 2021

### **ISRAEL GROUP NEWS**

In this issue, our global activities, latest publications, recent events and more.

---

## **Your opinion matters: Public consultation on the revision of the EU pharmaceutical legislation is now open**

19 October 2021

On 28 September 2021, the European Commission officially opened the public consultation on the revision of EU's general pharmaceutical legislation which will run for 12 weeks, until 21 December 2021.

---

## **An interview with Aldersgate Funding**

11 October 2021

In this podcast, DLA Piper partner Henry Quinlan interviews Jim Holding and Matthew Lo at Aldersgate Funding Limited, who shed some light on the advantages of litigation and arbitration funding; the types of claims eligible for funding; the process of funding a case; and the jurisdictional constraints on this type of financing.

---

## Can an AI system be named the inventor? In wake of EDVA decision, questions remain

23 September 2021

### AI OUTLOOK

Artificial intelligence is notable among the new technologies posing fundamental questions about the viability of the inventor's oath.

---

## The Pharmaceutical Corner

September 2021

*Teva v. Amicus* is the first lawsuit to test the reach of the CREATES Act. Expect more.

---

## New workplace sexual harassment laws passed – (some) Respect@Work recommendations become law

8 September 2021

After months of anticipation, the Australian Federal Government's Sex Discrimination and Fair Work (Respect at Work) Amendment Act 2021 has now passed both houses of Parliament. The amendment contains important reforms to address workplace sexual harassment.

---

## Learning the lessons on excessive pricing from Aspen

7 September 2021

### ANTITRUST MATTERS

Back in April 2017, The *Times* ran a story detailing how a drug giant had a "secret plan" to destroy a cancer medicine unless large price rises were agreed to by national purchasing authorities. A month later, the European Commission opened an investigation into Aspen.

---

## Israel Group News August 2021

16 August 2021

### ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

## The state of HealthTech and future opportunities

03 August 2021

### TECHLAW PODCAST

Podcast 41 of our TechLaw podcast series sees David Bell, Director at Hamleton Partners, leading M&A and corporate finance consultancy for companies with technology at their core, and DLA Piper Partner, Mark O'Connor, engage in an exciting conversation on the current innovations in HealthTech, as well as a futuristic outlook on the industry. Key highlights include the benefits of software as a medical device, macro factors influencing innovation and investment opportunities. Join David and Mark at our fifth European Technology Summit on the 5th October 2021 where they will be resuming this conversation. Register at our fifth European Technology Summit on the 5th October 2021.

DLA Piper TechLaw Podcast Series · The state of HealthTech and future opportunities

---

---

## Your opinion matters: Get ready for the revision of the EU general pharmaceutical legislation

6 July 2021

On 25 November 2020, the European Commission published its Pharmaceutical Strategy for Europe (Strategy). The Strategy highlights the EU's long-term objectives and priorities in the area of health and pharmaceutical and biotechnology-derived medicinal products. These priorities include concrete changes to existing EU pharmaceutical legislation.

---

## Patent eligibility of diagnostic methods in Australia confirmed: *Ariosa Diagnostics, Inc v Sequenom, Inc* [2021] FCAFC 101

29 June 2021

For many years, the following question awaited judicial determination under Australian law: is a DNA-based diagnostic method patent eligible subject matter? The Full Court of the Federal Court of Australia has confirmed that diagnostic methods involving the practical application of "natural phenomena" can be patentable inventions in Australia.

---

## The Pharmaceutical Corner

June 2021

We look at the underlying decision in *Immunex v. Sandoz* and the potential implications on pharma patent licensing strategies.

---

## Global M&A Intelligence Report 2021

23 June 2021

Our annual Global M&A Intelligence Report is based on an analysis of key deal terms in over 3,200 private M&A transactions on which we advised since 2015.

---

## Multi-jurisdiction guide for screening foreign investments

26 May 2021

The aim of this guide is not to substitute proper due diligence and specialized advice when conducting business, it will hopefully help the reader navigate the different FDI regimes. Particularly in this complex context and in view of the proliferation of new regimes, by explaining the key aspects of regimes including main issues to consider, thresholds and proceedings to take into consideration when investing in our globalized world.

---

## Israel Group News May 2021

1 May 2021

### [ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

---

## The New Romanian Food Supplements Law - what it means for consumers and for the healthcare business

6 April 2021

A complex piece of legislation governing food supplements was published on 1 April 2021, being debated since 2012 and confirmed by the Romanian Constitutional Court ruling in 2021. Law 56/2021 will be applicable starting with 3 April 2021. More detailed implementation rules

on manufacturing, sale and use are expected to be issued within 90 days.

---

## **The Pharmaceutical Corner**

30 March 2021

The opinion may render functional claiming more difficult, but functional claims that follow its guidance may still have an important role to play in pharmaceutical patents.

---

## **Understanding the USPTO guidance on patenting AI technologies**

30 March 2021

The USPTO guidance opens the door for applicants to obtain patent protection for their AI technologies.

---

## **United States imposes significant new export controls and sanctions on Russia and China**

23 March 2021

Reflecting a further hardening of US foreign policy and national security policy positions with those two countries.

---

## **Life Sciences in Ireland**

18 March 2021

Maura Dineen, Partner, outlines the significant scale and types of global Life Sciences organisations that make Ireland their home and how DLA Piper's globally-integrated Life Sciences team brings legal, scientific and medical know-how to deliver innovative solutions, enabled by technology.

---

## **Corruption Perceptions Index 2020 - a regional perspective**

11 February 2021

Last week Transparency International launched the 2020 edition of its Corruption Perceptions Index (CPI), which ranks 180 countries and territories by their perceived levels of public sector corruption, according to experts and business people, using a scale of zero to 100 (100 being very clean and zero being highly corrupt).

---

## **Russia Pharmaceuticals Sector Update - February 2021**

2 February 2021

### **[RUSSIA PHARMACEUTICALS SECTOR UPDATE](#)**

Possible new requirement to label medicines released before 1 February 2021.

---

## **The Qualified Maquiladora Approach Agreement has been renewed: Implications for multinationals' transfer pricing**

26 January 2021

US-based multinationals using the maquiladora structure to manufacture goods in Mexico are taking note.

---

---

## Israel Group News January 2021

19 January 2021

### [ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

---

## Boardroom Brexit: What the deal means for business

31 December 2020

### [BOARDROOM BREXIT](#)

Welcome to this last edition of Boardroom Brexit, marking the end of the negotiations and the agreement of a new trade deal, the UK-EU Trade and Cooperation Agreement (TCA). In this edition, we summarise the impact of the deal on all aspects of business operations in one place – please use the hyperlinks below to help you navigate the report.

---

## Boardroom Brexit: What the deal means for trade in goods

31 December 2020

### [BOARDROOM BREXIT](#)

What will the Trade and Cooperation Agreement mean for tariffs and quotas, rules of origin, technical barriers to trade, customs and product standards

---

## Boardroom Brexit: What the deal means for trade in services

31 December 2020

### [BOARDROOM BREXIT](#)

The TCA has substantial sectoral coverage, including professional and business services (e.g. legal, auditing, architectural services), delivery and telecommunication services, computer-related and digital services, financial services, research and development services, most transport services and environmental services.

---

## The Pharmaceutical Corner

22 December 2020

A precedential decision with potentially far-reaching impacts for future Hatch-Waxman litigation and generic-product launches.

---

## Brexit: Choice of Law, Jurisdiction, Enforcement, and Service

27 November 2020

This article looks at the impact of reaching the end of the Brexit transition period (at 11pm on 31 December 2020) on governing law, jurisdiction, enforcement, and service in contracts between UK entities and EU member state entities.

---

## Telehealth around the world: A global guide

19 November 2020

This Global Guide provides an overview of the current state of telehealth regulations worldwide and assists readers to identify the opportunities, challenges and risks, on a country-by-country basis.

---

## **Russia Pharmaceuticals Sector Update - November 2020**

9 November 2020

### **RUSSIA PHARMACEUTICALS SECTOR UPDATE**

The Russian Ministry of Healthcare is considering a mechanism for increasing permitted maximum sale prices for essential medicines that may face a shortage because of their manufacture becoming unprofitable.

---

## **Coronavirus: Directors' duties and making decisions in a crisis**

2 November 2020

Directors need to carefully consider how to address the risks of the ongoing COVID-19 pandemic within their business, given its impact on the global economy. As many companies are continuing to face significant, and increasing, cash flow pressure, directors should carefully consider their actions in the context of the legal framework.

---

## **China signs off on PRC Biosecurity Law: What this means for industry players in China**

21 October 2020

The Biosecurity Law establishes a comprehensive framework replacing the current somewhat piecemeal legislation.

---

## **Germany's New Foreign Direct Investments (FDI) Act took effect on 11 October 2020**

19 October 2020

In addition to the intended amendments to the Foreign Trade and Payments Act Germany's Federal Government on 20 May 2020 has decided on a bill that broadens the scope and the scrutiny with regard to foreign investments.

---

## **China Enforces Tax Collection on Employees Working for Chinese-invested Enterprises Overseas**

16 October 2020

With the recent IIT reform in 2019, and the introduction of a number of implementation rules (particularly the tax policy on overseas income), it appears the China tax authorities are taking a harder stance on how overseas income derived by China tax residents will be taxed in China, starting with Chinese expatriates working for Chinese state-owned enterprises.

---

## **COVID-19 – Galvanising your business against supply chain and customer insolvency risk**

7 October 2020

The risk of unforeseen counterparty customer or supplier financial distress and failure amidst the on-going challenges for businesses from COVID-19 means that pre-emptive legal and operational protections against the risk of heavy financial loss or business disruption from customer/supplier failure are more valuable than ever.

---

## **Israel Group News October 2020**

7 October 2020

## ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

### Mass layoffs and collective redundancies guide

6 October 2020

As COVID-19 continues to impact the global economy in unprecedented ways, companies that have had to scale back or shut down operations are bracing for what the next few months will bring, and what this means for their workforces. In this guide, we examine key considerations for employers looking to make permanent reductions in force across APAC.

---

### Coronavirus Resource Center: Our global repository of insights and events

30 September 2020

A central repository for our reports and commentary on the legal and regulatory concerns arising from the pandemic.

---

### New CFIUS regulations change mandatory filing requirements and increase the importance of US export controls

30 September 2020

The new rule modifies the criteria that trigger a mandatory filing with CFIUS, potentially subjecting more transactions to mandatory CFIUS review.

---

### Philadelphia grows privacy capabilities with a new arrival

30 September 2020

Ronald Plesco, an internationally known information security and privacy lawyer, has joined our Philadelphia office.

---

### The Pharmaceutical Corner

30 September 2020

In this inaugural column, we look at the implications of IPR and PGR proceedings in Hatch Waxman litigation.

---

### Digital Therapeutics - evolution and entry into mainstream healthcare

18 September 2020

Research undertaken by DLA Piper's Life Sciences sector in conjunction with The Lawyer seeks to understand the current developments in the field of digital therapeutics, looking at key questions that need to be addressed if these products are to become mainstream components of health systems across the world.

---

### Human rights compliance programmes in the Life Sciences sector

10 September 2020

The risk of adverse environmental, social or human rights impacts is one that Life Sciences businesses will be familiar with.

---

## Human rights compliance programmes: Why now?

10 September 2020

Businesses are increasingly required to identify and manage their involvement in adverse environmental and social impacts throughout their organisations and supply chains. Previously, drivers for developing human rights compliance programmes have included reputation risk and compliance with best practice and “soft law” standards.

---

## Russia Pharmaceuticals Sector Update - September 2020

3 September 2020

### [RUSSIA PHARMACEUTICALS SECTOR UPDATE](#)

Government approves regulations on granting organisations subsidies to partially reimburse expenses incurred in connection with product certification and homologation in foreign markets.

---

## Details of the second tranche of Hong Kong’s Employment Support Scheme released

24 August 2020

On 18 August 2020 the Hong Kong government announced details surrounding the second tranche of the Employment Support Scheme. While the majority of the rules surrounding the second tranche remain largely the same as the first tranche, there are new penalties for employers who have fallen foul of a number of nebulous terms.

---

## Release of exposure draft legislation for major reforms to Australia’s Foreign Investment Framework

10 August 2020

Many governments around the world have been strengthening their laws relating to foreign investment. Australia is no exception to this development and has just released proposed sweeping reforms to its foreign investment regime. In this article, we provide a high level overview of the key proposed amendments and our thoughts on how some of those proposals are likely to affect foreign investment into Australia.

---

## Vlog series: How to raise equity capital during the Coronavirus pandemic (UK)

4 August 2020

The first half of 2020 has seen an unprecedented volume of activity by companies raising capital through follow-on equity offerings on the London Stock Exchange in response to the Coronavirus pandemic. There have been over 140 equity issues on the London Stock Exchange’s main market or AIM since 20 March 2020 raising more than GBP14 billion.

---

## Hong Kong Government increases statutory entitlement for maternity leave

16 July 2020

On 10 October 2018, the Chief Executive stated in her policy address that the government proposed to increase the statutory maternity leave entitlement from ten to 14 weeks.

---

## Israel Group News July 2020

8 July 2020

## ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

### The legal challenges facing the vaping industry in the EU/UK and the US: An overview and a look ahead

7 July 2020

Notes as the industry matures.

---

### Russia Pharmaceuticals Sector Update - July 2020

7 July 2020

#### RUSSIA PHARMACEUTICALS SECTOR UPDATE

On 17 March 2020 the Russian President signed an Order that allowed the distance sale of over-the-counter medicines. However, at that time, such sales were conditioned on federal legislation being adopted and the Russian Government outlining further mechanisms for such sales.

---

### Clinical trials during the COVID-19 pandemic: A global guide

2 July 2020

The consequences of the COVID-19 pandemic continue to develop dynamically. Some countries are beginning to ease lockdown measures, whilst others retain or even impose new restrictions. The situation continues to impact the ability to conduct clinical trials on a global scale. Pharmaceutical companies need to address even more challenges to ensure the continuity of trials on human medicines.

---

### A go-to firm for defending patent cases

30 June 2020

Recognition from *Law360*

---

### Atlanta expands privacy capabilities

30 June 2020

Lael Bellamy's arrival bolsters our data protection, privacy and security capabilities throughout the firm.

---

### Changes to Hong Kong anti-discrimination legislation

30 June 2020

Anti-discrimination laws in Hong Kong have undergone a series of changes over the past few years.

---

### Hatch-Waxman Litigation 101: The Orange Book and the Paragraph IV Notice Letter

30 June 2020

A few of the key issues that must be addressed before a Hatch-Waxman suit is filed.

---

---

## **Intellectual property rights are a renewed focus as the world looks beyond a global viral outbreak**

30 June 2020

A few key IP-related considerations for companies, whether they are seeking to expand into new markets or looking to preserve their place in an existing market.

---

## **Northern California bolsters telecom and regulatory practice**

30 June 2020

Regulatory and telecom attorney Kristin Jacobson has joined our Northern California office in Sacramento.

---

## **Washington, DC grows technology capabilities with two new arrivals**

30 June 2020

Marius Domokos and Justin Ilhwan Park have joined our Washington, DC practice.

---

## **First emerging technologies identified and controlled for export in the EAR**

26 June 2020

The designation also makes these a "critical technology," giving CFIUS jurisdiction over foreign investments in US businesses that engage with these items.

---

## **Therapies for COVID-19: Two major developments**

25 June 2020

The developments, one negative and one positive, involve widely available medications.

---

## **CFIUS encourages public to provide tips and referrals**

24 June 2020

The new webpage encourages tips and referrals about non-notified deals, violations of CFIUS mitigation measures, and other matters that raise national security risk.

---

## **Dublin office anniversary**

19 June 2020

Our people in the Irish practice are celebrating our first anniversary and the substantial growth that has been achieved in just 12 months.

---

## **Business protection: An Interactive guide**

18 June 2020

Global companies are at risk of their data and confidential information being leaked to competitors, especially when key employees leave. Protecting the integrity of new formulations and trade secrets is crucial, particularly for life sciences companies, to holding a competitive advantage and building success.

---

## **Australia tightens rules on foreign investment**

17 June 2020

In this article we summarise the tax-related developments from early June 2020, as Australia takes a more stringent approach towards compliance procedures involving foreign investments.

---

## **Preparing for global class actions arising from COVID-19**

28 May 2020

The risk to companies of global and cross-border class action and collective redress proceedings is rising.

---

## **Chinese and other emerging market companies listed in the US face increased scrutiny from Congress and Nasdaq**

27 May 2020

Within a span of two days, the US Senate, House and Nasdaq each took steps to safeguard investors in the US capital markets.

---

## **PFAS: in California, regulators put cleanup levels on hold, but announce major data hunt**

7 MAR 2019

This data hunt will affect thousands of facilities, drinking water systems and private drinking water well owners.

---

## **Intellectual Property and Technology News (United States), Issue 23, Q3 2014**

10 SEP 2014

### **INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS**

Our Intellectual Property and Technology News reports on worldwide developments in IP and technology law, offering perspectives, analysis and visionary ideas.

---

## **Distributing patent rights between affiliates: guidelines to support enforcement rights around the world**

16 NOV 2015

Considering a few issues at the outset when rights are distributed between Parent and Affiliate (or between multiple affiliates) may avoid difficulties in the future when a company wants to enforce patent rights.

---

## **EVENTS**

## [Previous](#)

### **UPC: What should in-house teams be doing now?**

9 May 2022  
10:00 AM - 11:00 AM ET  
3:00 PM - 4:00 PM BST

---

### **Using AI to monitor your compliance risks**

31 March 2022  
Webinar

---

### **International Women's Day**

10 March 2022  
Webinar

---

### **Beyond Politics: The Person Behind the Policies**

16 February 2022  
Webinar

---

### **Embracing Digital Evolution**

15 September 2021  
Webinar

---

### **The societal, medical and economic consequences of the global pandemic and the lessons we can learn**

22 March 2021  
Webinar

---

### **EDPB recommendations for safeguarding data transfers after Schrems II**

19 November 2020  
Webinar

---

### **COVID-19: Present and future**

14 July 2020  
Webinar

---

## NEWS

---

### **DLA Piper advises Philip Morris International Inc. on USD16 billion recommended cash offer for Swedish Match**

12 May 2022

DLA Piper, as International Counsel, is advising Philip Morris Holland Holdings B.V., an Affiliate of Philip Morris International Inc. (PMI), on its USD16 billion recommended public offer to the shareholders of Swedish Match AB (Swedish Match), a public limited company with shares listed on Nasdaq Stockholm.

---

### **DLA Piper advises Linus Health on its acquisition of Kinesis Health Technologies**

6 April 2022

DLA Piper has advised Boston-based digital health company Linus Health on its acquisition of Kinesis Health Technologies, a Dublin-based leader in physical function assessment for older adults.

---

### **DLA Piper advises AOC as anchor shareholder of Formycon on acquisition of biosimilar assets**

31 March 2022

DLA Piper has advised Active Ownership Capital in connection with Formycon AG's acquisition of the biosimilar candidates FYB201 and FYB202 from ATHOS Group.

---

### **DLA Piper strengthens its litigation and international arbitration practice with partner Dr Marc Jacob**

16 March 2022

DLA Piper will strengthen its Litigation & Regulatory practice group with the appointment of Marc Jacob as a new partner in the Frankfurt office, effective 1 April 2022. He joins DLA Piper from Shearman & Sterling, where he practised litigation and international arbitration since 2013.

---

### **DLA Piper support Leafy Tunnel on Europe's first cannabis and psychedelics fund launch**

31 January 2022

DLA Piper Cannabis practice has advised Leafy Tunnel on the first closing of its Guernsey-based fund, established to invest in both medicinal cannabis and psychedelic companies; the first of its type in Europe.

---

### **DLA Piper advises Breffi on RUB750m investment from Elbrus Capital**

13 January 2022

DLA Piper has advised Breffi, a Russian omnichannel pharmaceutical marketing company, on a RUB750 million investment from Elbrus Capital, a Russia and CIS-focused private equity firm.

---

### **DLA Piper advises Russia's healthcare platform NaPopravku on USD5m investment round**

15 December 2021

DLA Piper has advised NaPopravku, a Russian online appointment service for clinics and doctors, on its USD5 million investment round led by Swedish investment company VNV Global, Russian investment holding Avenir and Malaysia's JobStreet.com founder Mark Chang.

---

### **DLA Piper advises Tentamus Group on investment in Lambda Científica and Actitum in Mexico**

6 September 2021

DLA Piper has advised Tentamus Group on an investment in Lambda Científica, S.A. de C.V. (Lambda) and Actitum MDC, S. de R.L. de C.V. (Actitum), leading analytical laboratories in the pharmaceutical sector in Mexico.

---

### **DLA Piper advises BestDoctor on USD26m Series B investment round**

14 July 2021

DLA Piper has advised BestDoctor, which is creating Russia's first health management system based on hi-tech medical insurance services, on the USD26 million Series B investment round.

---

### **DLA Piper advises HUTCHMED on its Hong Kong IPO**

8 July 2021

DLA Piper is advising global biopharmaceutical company HUTCHMED on its Hong Kong public offering. This will be the third listing for the company, following its first on London's AIM exchange and then NASDAQ in the US.

---

### **DLA Piper advises Poland's Copernicus on its sale to Nemera**

29 October 2020

DLA Piper has advised Copernicus, regarded as one of the most valued innovative companies in the Polish health sector, and its founders on its sale to Nemera, a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries.

---

### **DLA Piper advises VNV Global on c. USD2 million investment in Russia's healthcare platform NaPopravku**

23 September 2020

DLA Piper has advised VNV Global, a Swedish investment company, on its circa USD2 million investment (jointly with other investors) in NaPopravku, a Russian online appointment service for clinics and doctors, to develop a mobile application and expand into the regions.

---

### **DLA Piper advises BestDoctor on USD4.5 million investment round**

24 July 2020

DLA Piper has advised BestDoctor, a Russian medical insurance startup, on its US\$4.5 million investment round from a group of private investors led by Target Global, AddVenture and LVL1.

---

### **DLA Piper advises Dechra Pharmaceuticals on GBP133.4m share placing**

5 June 2020

DLA Piper has advised FTSE 250 veterinary pharmaceuticals business Dechra Pharmaceuticals (Dechra) on the placing of 5,1 million new ordinary shares raising GBP133.4 million.

---

## DLA Piper advises Ping An on investment in Berlin health start-up Plusdental

29 May 2020

DLA Piper has advised Hong Kong based Ping An Global Voyager Fund (Global Voyager Fund) on an investment in the Berlin based health start-up Plusdental in a EUR32 million financing round.

---

## In Russia

---

Our international team of lawyers, consisting of Russian, English and US qualified lawyers, are experienced in a wide range of business transactions, including franchising, brand development, life sciences, pharmaceuticals and related matters. We advise international and local pharmaceutical companies on issues related to Russian regulatory framework for manufacturing, circulation and pricing of pharmaceuticals. We also offer advice on various aspects relating to compliance with regulatory requirements for importation and distribution of medical products and medical devices, and assist clients in the licensing of medical product manufacturing technology. Finally, we also extensively advise international and local pharmaceutical companies in various forms of M&A and private equity transactions.

Sophisticated biotechnology and pharmaceutical clients want and need their lawyers to understand their business, anticipate legal problems, know how others in the industry are addressing emerging issues, know what regulators and tax professionals think, and be able to provide timely answers. It takes extensive industry involvement to provide this level of service. This is why DLA Piper is the logical choice for life sciences companies seeking a strategic legal partner in Russia.

### EXPERIENCE

- Advising a major Japanese pharmaceutical company in a competitive sale process for the acquisition of over-the-counter and food supplement brands in Russia worth US\$ 1 billion, including due diligence and full transaction support.
- Advising a major Japanese pharmaceutical company in a competitive sale process for the acquisition of over-the-counter brands in the CIS worth US\$ 500 million, including due diligence and full transaction support.
- Advising a large Hungarian pharmaceutical company in a competitive sale process for the acquisition of a US\$ 100 million asset in Russia, including due diligence and full transaction support.
- Advising a large Russian group of companies on the sale of the over-the-counter pharmaceuticals company in Russia to an international pharmaceuticals company headquartered in Canada.
- Advising a Russian company and its group involved in organization of clinical trials (medical testing at preregistration phase) and operating in various jurisdictions across Eastern Europe and in the US, on various structuring issues in connection with the company's contemplated expansion to Western European markets, including due diligence.
- Acting for a German multinational chemical and pharmaceutical company in reorganisation and restructuring in relation to the merger of the Russian subsidiaries of Bayer and Schering-Plough (as part of the global Bayer-Schering merger), including advice on both general corporate and tax issues, and legal and tax due diligence of draft agreements regarding the Russian distribution campaign.
- Providing legal assistance to a large US life sciences company with regard to a full pre-acquisition due diligence of a St Petersburg-based pharmaceutical company.
- Advising a leading Italian life sciences multinational company on the restructuring of its US\$ 90 million IP assets acquired as part of the acquisition of a Russian bio-pharma target company, including extensive tax and IP advice specifically with respect to acquiring and restructuring all the license operations and intellectual property in Russia for the Italian group, involving the structuring of several patents, industrial designs and over 100 trademarks use for drugs and biologically active additions.
- Advising a US based global healthcare company on a joint venture project related to import and distribution of pharmaceuticals in Russia, including advice on Russian pricing regulations.
- Acting for a leading Norwegian engineering and construction company working across a number of industries, including pharmaceuticals,

in its acquisition of a Russian engineering bureau. The mandate included significant regulatory support in addition to the M&A work.

- Advising a Swiss based global healthcare company on setting up a EUR 80 million greenfield project in Special Economic Zone (SEZ) Novoorlovskaya, St Petersburg, including registration of a legal entity in St Petersburg, analysis of the SEZ agreement required for granting Novartis SEZ resident status, conducting due diligence in relation to the land plot in order to detect key risks.
- Advising a leading global biopharma company in relation to general employment law matters, including reorganisation.
- Advising a leading international medical technology company and developer of hearing implants system, in the planning, structuring, negotiation and document preparation for the completion of a know-how license and distribution relationship for the manufacture and sale of medical devices in Russia.
- Representing a major world-wide pharmaceutical company in relation to the stoppage of unauthorized use of five domain names by a third party and the related settlement agreement.
- Representing a major German personal-care company in a landmark domain name cyber-squatting case.
- Advising a number of clients on regulatory and practical aspects of structuring clinical trials.

## Sustainability and ESG

---

Sustainability and resilience are core business issues in the life sciences sector, given the sector's central role in addressing systemic global challenges including pandemics, access to medicine, and fundamental human rights. Although the specific factors from a sustainability, environmental, social and governance (ESG) perspective in the life science industry differ from those of other industries, creating new and sustainable value in the life science space will depend upon how companies address relevant ESG risks. Boards must actively identify such ESG risks and ensure that they are efficiently mitigated in order for their companies to avoid pitfalls and ensure compliance with evolving regulation around the globe – and also to maintain their competitive position and profitability.

On the basis of our experience in the sector, we believe the following sustainability-related themes to be the core ESG issues that will continue to affect life science businesses:

- **Access and affordability:** Addressing unmet healthcare needs, increasing access to affordable essential medicines and strengthening health systems around the world are all fundamental to social and economic progress. The coronavirus disease 2019 (COVID-19) has further highlighted the importance of the life sciences sector in addressing these challenges. Against this background, international life science business will need to engage in discussions about and develop strategies addressing these issues across the world, particularly with regard to improving the situation in lesser developed countries.
- **Supply chain compliance:** Many governments and regulators around the world are implementing tighter rules on supply chain compliance. To retain their license to operate, life sciences companies must adhere to an evolving set of global laws and regulations. Furthermore, transparency requirements, as well as responsibility and liability for global suppliers are increasing. This ongoing regulatory shift, and the increased likelihood of litigation which goes with it, will have a significant impact on the global life sciences industry. This is because supply chains are often particularly lengthy and complex and influenced by many different internal and external factors that are hard to monitor and control.
- **Product safety and quality:** Fake or substandard medicines lead to hundreds of thousands of deaths each year. Drug safety, along with protecting health consumers from counterfeit medicines and drug diversion, are integral to ensuring public health and maintaining trust and confidence in the life sciences sector. Consequently, life science companies will need to put increasing focus on ensuring product safety as well as maintaining secure distribution channels to patients.
- **Business ethics:** There is increasing stakeholder attention, including from regulators and policymakers and also from providers of capital, on transparency and ethics in business dealings with healthcare providers and medical practitioners for the sale and use of products, as well as in relation to lobbying and advocacy activities. The way in which businesses respond to these expectations can have a direct impact upon their reputation, their cost of capital and ultimately upon their license to operate.
- **Transparency and access in clinical trials:** Stakeholders increasingly expect transparency in clinical trials and wider access to trial data for scientific exchange and research. There is a bright spotlight on participant safety and privacy. Businesses are demanding more effective information sharing to enable informed decision-making and consent, along with post-trial access to results. Technology and collaborative partnerships with patient and health worker groups enable wider representative demographic populations to participate in clinical trials.
- **Sustainable sourcing, product lifecycles and a circular economy:** Markets demand greater visibility across product lifecycles, businesses make commitments to net-zero decarbonisation and business model innovation is driven by circular economy concepts. Underpinned by an increasingly complex transnational regulatory landscape, these developments are changing the way raw materials

are sourced; how products are designed, manufactured, packaged, sold, reused or recycled; how waste and hazardous material is treated; and how wider environmental and social impacts relating to issues like emissions, plastics, water use, biodiversity loss, labour conditions and community impacts are managed.

- **Net-zero decarbonisation and optimisation of processes:** In striving to decarbonise the economy, businesses are implementing commitments to Science Based Targets, increasing energy efficiency and reducing carbon output, decreasing dependency on fossil fuels and increasing the use of renewables. The implementation of these initiatives is creating operational efficiencies, optimising the drug manufacturing, packaging and distribution process and reducing costs across the sector.

---

To discuss the implications of these issues for your business, please contact our ESG leaders.



## Life Sciences

As the legal matters confronting our life science clients are varied, so are the skill sets we employ. DLA Piper's life sciences team comprises lawyers with legal, scientific and medical knowledge who understand the complexity of the business and regulatory environments in which our clients operate.

The challenges facing today's biotechnology and medical device companies are greater than ever. For companies to take promising therapies from the laboratory to the market, they must protect those therapies from IP, regulatory and reputational risks. Furthermore, the last few years have seen increasing pressure from many sides: demand for greater shareholder return, loss of key revenue streams due to patent expiration or generic challenges, fierce competition in key therapeutic areas, pricing pressures from health care payors, increased government regulation beyond core safety issues, rising costs of R&D, challenges in maximizing return in emerging markets and aggressive government enforcement action.

Our life sciences sector team is one of the largest and most active of any law firm. Operating as one team across more than 30 jurisdictions, we combine subject matter experience with considerable knowledge of the sector, including the scientific, medical, regulatory, commercial and enforcement environments facing our biopharmaceutical, medical device, research and diagnostics clients.

DLA Piper's team includes award-winning lawyers practicing litigation, compliance and investigations, IP strategy and enforcement, M&A, licensing and distribution and clinical trial advice. They also support clients across all other areas needed to address risk, including government affairs, environmental law, import/export, tax, real estate and employment law. Many of our lawyers are former sector professionals, many have PhDs or other advanced degrees in the life sciences field and others are former government officials or prosecutors.

Recognizing that our clients' needs vary, we rapidly organize and customize our client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company. These teams are supported by international and local practitioners to efficiently meet the demands of the matter.

Our cutting-edge staffing, budgeting and billing systems, created specifically to assist our global life science clients, ensure that our teams deliver value in addition to great results.

Our life sciences team helps clients solve their biggest challenges every day. Examples of our experience include:

- Conducting a sensitive investigation in China
- Negotiating a complex multi-country distribution deal in Latin America
- Acting as National Counsel on a mass tort in the US
- Helping sell or acquire a major business asset
- Advising on implementation of transparency laws or the impact of other new legislation
- Devising a risk mitigation plan for a key product
- Negotiating a large vaccine contract with a global NGO
- Counselling on a multi-jurisdictional clinical trial
- Advising on the downsizing of employees in Europe
- Supporting global business conduct and compliance functions
- Outsourcing critical R&D or IT functions
- Devising an IP strategy for a promising new therapy
- Negotiating a worldwide licensing and collaboration deal
- Protecting a blockbuster drug in patent litigation

## INSIGHTS

---

### Publications

#### Global M&A Intelligence Report 2022

3 May 2022

Our annual Global M&A Intelligence Report is based on an analysis of key deal terms in almost 5,000 private M&A transactions on which we have advised since 2015.

---

#### Life Sciences

29 April 2022

A brief description of key legislative changes in the health sector.

---

#### Israel Group News April 2022

28 April 2022

#### ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

#### US escalates its sanctions regime against Russia, targeting its financial system

28 February 2022

#### GLOBAL SANCTIONS ALERT

And additional measures are expected to be announced by the US and its allies in the coming days

---

#### Aiscension: an AI tool to ensure effective risk management by detecting anti-competitive practice

24 February 2022

Anti-competitive activity has been rife in companies for centuries and there are many who like to take the ostrich approach and bury their head in the sand. However, it is known that this approach to risk management is ineffective should the regulators come looking, and with fines of up to 10% of global turnover, it is a big risk to take.

---

## **New US sanctions in response to Russia's actions against Ukraine**

23 February 2022

### **GLOBAL SANCTIONS ALERT**

Additional sanctions are expected that will target Russia's financial, technology, and defense sectors.

---

## **Israel Group News January 2022**

24 January 2022

### **ISRAEL GROUP NEWS**

In this issue, our global activities, latest publications, recent events and more.

---

## **A legal overview**

4 January 2022

### **UNDERSTANDING THE UK NATIONAL SECURITY & INVESTMENT REGIME PODCAST**

In episode 2 of our podcast series we discuss the legal context of the regime: how it will operate and the implications for businesses. In particular, the legislation - which comes into force today, 4 January - has wide reaching implications for M&A involving businesses or assets connected with the UK.

---

## **Supporting the health of your health system: 2022**

3 January 2022

Helping you tend to healthcare system wellness throughout the business life cycle.

---

## **Global COVID-19 Vaccine Guide for Employers**

22 December 2021

*Updated on 21 January 2022*

As the scientific response to the COVID-19 pandemic develops, many employers are considering what their approach should be to the issues around vaccination for their workforce, with a view to accelerating a return to some kind of normality. This is an area where law, guidance and best practice is likely to develop rapidly and there is no one-size-fits-all solution, particularly for multinational employers. The risks, challenges and benefits will vary depending on the profile of the workforce and nature and location of the business.

In our newly launched global guide we set out some of the key considerations with regard to requiring or encouraging employees to be vaccinated and highlight some of the differences in risk around the world. These are complex and evolving issues and the situation should be kept under review as vaccine programmes become more widely available, economies and borders begin to open up again and more people return to the workplace.

---

## **Get ready for collective actions in Europe**

6 December 2021

Our client risk report "Get ready for collective actions in Europe", summarises the key trends and risks that consumer businesses in Europe may face following the Collective Redress Directive's implementation at the end of 2022.

---

## **The Industry Agreement on Chemical, Petrochemical, Biotechnological and Chemical-Pharmaceutical Organisations to be extended in Russia**

1 December 2021

On 11 November 2021, the Russian Ministry of Labour published in the Russian Gazette the Additional Agreement on the Prolongation for 2022-2024 of the Industry Agreement on Chemical, Petrochemical, Biotechnological and Chemical-Pharmaceutical Organisations (Agreement).

---

## **European Commission's Proposals for reform of AIFMD, UCITS Directive and the ELTIF regime**

26 November 2021

Following its review of the scope and functioning of the Alternative Investment Funds Manager Directive<sup>1</sup> (AIFMD), the European Commission (the Commission) has concluded that the AIFMD's standards for ensuring high levels of investor protection are mostly effective, but that amendments are required which are intended to be targeted in scope, but may have far-reaching effects.

The Commission has now published new legislative amendments to AIFMD, the UCITS Directive<sup>2</sup> (UCITSD) and the ELTIF Regulation<sup>3</sup> (ELTIF Regulation) (the Commission Proposal). The proposed amendments set out in the Commission Proposal will be introduced by way of an omnibus directive amending the AIFMD, UCITSD and the ELTIF Regulation.<sup>4</sup>

---

## **The Glasgow Climate Pact: What does it mean for Business?**

23 November 2021

In this article, members of our Sustainability and ESG Steering Committee share their thoughts on eight key themes emerging from COP26 and what they mean for business.

---

## **Israel Group News October 2021**

25 October 2021

### **ISRAEL GROUP NEWS**

In this issue, our global activities, latest publications, recent events and more.

---

## **Your opinion matters: Public consultation on the revision of the EU pharmaceutical legislation is now open**

19 October 2021

On 28 September 2021, the European Commission officially opened the public consultation on the revision of EU's general pharmaceutical legislation which will run for 12 weeks, until 21 December 2021.

---

## **An interview with Aldersgate Funding**

11 October 2021

In this podcast, DLA Piper partner Henry Quinlan interviews Jim Holding and Matthew Lo at Aldersgate Funding Limited, who shed some

---

light on the advantages of litigation and arbitration funding; the types of claims eligible for funding; the process of funding a case; and the jurisdictional constraints on this type of financing.

DLA Piper · Aldersgate Funding on how litigation funding can help your business

---

## Can an AI system be named the inventor? In wake of EDVA decision, questions remain

23 September 2021

### AI OUTLOOK

Artificial intelligence is notable among the new technologies posing fundamental questions about the viability of the inventor's oath.

---

## The Pharmaceutical Corner

September 2021

*Teva v. Amicus* is the first lawsuit to test the reach of the CREATES Act. Expect more.

---

## New workplace sexual harassment laws passed – (some) Respect@Work recommendations become law

8 September 2021

After months of anticipation, the Australian Federal Government's Sex Discrimination and Fair Work (Respect at Work) Amendment Act 2021 has now passed both houses of Parliament. The amendment contains important reforms to address workplace sexual harassment.

---

## Learning the lessons on excessive pricing from Aspen

7 September 2021

### ANTITRUST MATTERS

Back in April 2017, The *Times* ran a story detailing how a drug giant had a "secret plan" to destroy a cancer medicine unless large price rises were agreed to by national purchasing authorities. A month later, the European Commission opened an investigation into Aspen.

---

## Israel Group News August 2021

16 August 2021

### ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

## The state of HealthTech and future opportunities

03 August 2021

### TECHLAW PODCAST

Podcast 41 of our TechLaw podcast series sees David Bell, Director at Hambleton Partners, leading M&A and corporate finance consultancy for companies with technology at their core, and DLA Piper Partner, Mark O'Connor, engage in an exciting conversation on the current innovations in HealthTech, as well as a futuristic outlook on the industry. Key highlights include the benefits of software as a medical device, macro factors influencing innovation and investment opportunities. Join David and Mark at our fifth European Technology Summit on the 5th

October 2021 where they will be resuming this conversation. Register at our fifth European Technology Summit on the 5th October 2021.

DLA Piper TechLaw Podcast Series · The state of HealthTech and future opportunities

---

## Your opinion matters: Get ready for the revision of the EU general pharmaceutical legislation

6 July 2021

On 25 November 2020, the European Commission published its Pharmaceutical Strategy for Europe (Strategy). The Strategy highlights the EU's long-term objectives and priorities in the area of health and pharmaceutical and biotechnology-derived medicinal products. These priorities include concrete changes to existing EU pharmaceutical legislation.

---

## Patent eligibility of diagnostic methods in Australia confirmed: *Ariosa Diagnostics, Inc v Sequenom, Inc* [2021] FCAFC 101

29 June 2021

For many years, the following question awaited judicial determination under Australian law: is a DNA-based diagnostic method patent eligible subject matter? The Full Court of the Federal Court of Australia has confirmed that diagnostic methods involving the practical application of "natural phenomena" can be patentable inventions in Australia.

---

## The Pharmaceutical Corner

June 2021

We look at the underlying decision in *Immunex v. Sandoz* and the potential implications on pharma patent licensing strategies.

---

## Global M&A Intelligence Report 2021

23 June 2021

Our annual Global M&A Intelligence Report is based on an analysis of key deal terms in over 3,200 private M&A transactions on which we advised since 2015.

---

## Multi-jurisdiction guide for screening foreign investments

26 May 2021

The aim of this guide is not to substitute proper due diligence and specialized advice when conducting business, it will hopefully help the reader navigate the different FDI regimes. Particularly in this complex context and in view of the proliferation of new regimes, by explaining the key aspects of regimes including main issues to consider, thresholds and proceedings to take into consideration when investing in our globalized world.

---

## Israel Group News May 2021

1 May 2021

### [ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

---

## The New Romanian Food Supplements Law - what it means for consumers and for the healthcare business

6 April 2021

A complex piece of legislation governing food supplements was published on 1 April 2021, being debated since 2012 and confirmed by the Romanian Constitutional Court ruling in 2021. Law 56/2021 will be applicable starting with 3 April 2021. More detailed implementation rules on manufacturing, sale and use are expected to be issued within 90 days.

---

## **The Pharmaceutical Corner**

30 March 2021

The opinion may render functional claiming more difficult, but functional claims that follow its guidance may still have an important role to play in pharmaceutical patents.

---

## **Understanding the USPTO guidance on patenting AI technologies**

30 March 2021

The USPTO guidance opens the door for applicants to obtain patent protection for their AI technologies.

---

## **United States imposes significant new export controls and sanctions on Russia and China**

23 March 2021

Reflecting a further hardening of US foreign policy and national security policy positions with those two countries.

---

## **Life Sciences in Ireland**

18 March 2021

Maura Dineen, Partner, outlines the significant scale and types of global Life Sciences organisations that make Ireland their home and how DLA Piper's globally-integrated Life Sciences team brings legal, scientific and medical know-how to deliver innovative solutions, enabled by technology.

---

## **Corruption Perceptions Index 2020 - a regional perspective**

11 February 2021

Last week Transparency International launched the 2020 edition of its Corruption Perceptions Index (CPI), which ranks 180 countries and territories by their perceived levels of public sector corruption, according to experts and business people, using a scale of zero to 100 (100 being very clean and zero being highly corrupt).

---

## **Russia Pharmaceuticals Sector Update - February 2021**

2 February 2021

### **[RUSSIA PHARMACEUTICALS SECTOR UPDATE](#)**

Possible new requirement to label medicines released before 1 February 2021.

---

## **The Qualified Maquiladora Approach Agreement has been renewed: Implications for multinationals' transfer pricing**

26 January 2021

US-based multinationals using the maquiladora structure to manufacture goods in Mexico are taking note.

---

## Israel Group News January 2021

19 January 2021

### [ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

---

## Boardroom Brexit: What the deal means for business

31 December 2020

### [BOARDROOM BREXIT](#)

Welcome to this last edition of Boardroom Brexit, marking the end of the negotiations and the agreement of a new trade deal, the UK-EU Trade and Cooperation Agreement (TCA). In this edition, we summarise the impact of the deal on all aspects of business operations in one place – please use the hyperlinks below to help you navigate the report.

---

## Boardroom Brexit: What the deal means for trade in goods

31 December 2020

### [BOARDROOM BREXIT](#)

What will the Trade and Cooperation Agreement mean for tariffs and quotas, rules of origin, technical barriers to trade, customs and product standards

---

## Boardroom Brexit: What the deal means for trade in services

31 December 2020

### [BOARDROOM BREXIT](#)

The TCA has substantial sectoral coverage, including professional and business services (e.g. legal, auditing, architectural services), delivery and telecommunication services, computer-related and digital services, financial services, research and development services, most transport services and environmental services.

---

## The Pharmaceutical Corner

22 December 2020

A precedential decision with potentially far-reaching impacts for future Hatch-Waxman litigation and generic-product launches.

---

## Brexit: Choice of Law, Jurisdiction, Enforcement, and Service

27 November 2020

This article looks at the impact of reaching the end of the Brexit transition period (at 11pm on 31 December 2020) on governing law, jurisdiction, enforcement, and service in contracts between UK entities and EU member state entities.

---

## Telehealth around the world: A global guide

19 November 2020

This Global Guide provides an overview of the current state of telehealth regulations worldwide and assists readers to identify the opportunities, challenges and risks, on a country-by-country basis.

---

## **Russia Pharmaceuticals Sector Update - November 2020**

9 November 2020

### **RUSSIA PHARMACEUTICALS SECTOR UPDATE**

The Russian Ministry of Healthcare is considering a mechanism for increasing permitted maximum sale prices for essential medicines that may face a shortage because of their manufacture becoming unprofitable.

---

## **Coronavirus: Directors' duties and making decisions in a crisis**

2 November 2020

Directors need to carefully consider how to address the risks of the ongoing COVID-19 pandemic within their business, given its impact on the global economy. As many companies are continuing to face significant, and increasing, cash flow pressure, directors should carefully consider their actions in the context of the legal framework.

---

## **China signs off on PRC Biosecurity Law: What this means for industry players in China**

21 October 2020

The Biosecurity Law establishes a comprehensive framework replacing the current somewhat piecemeal legislation.

---

## **Germany's New Foreign Direct Investments (FDI) Act took effect on 11 October 2020**

19 October 2020

In addition to the intended amendments to the Foreign Trade and Payments Act Germany's Federal Government on 20 May 2020 has decided on a bill that broadens the scope and the scrutiny with regard to foreign investments.

---

## **China Enforces Tax Collection on Employees Working for Chinese-invested Enterprises Overseas**

16 October 2020

With the recent IIT reform in 2019, and the introduction of a number of implementation rules (particularly the tax policy on overseas income), it appears the China tax authorities are taking a harder stance on how overseas income derived by China tax residents will be taxed in China, starting with Chinese expatriates working for Chinese state-owned enterprises.

---

## **COVID-19 – Galvanising your business against supply chain and customer insolvency risk**

7 October 2020

The risk of unforeseen counterparty customer or supplier financial distress and failure amidst the on-going challenges for businesses from COVID-19 means that pre-emptive legal and operational protections against the risk of heavy financial loss or business disruption from customer/supplier failure are more valuable than ever.

---

## Israel Group News October 2020

7 October 2020

### ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

#### Mass layoffs and collective redundancies guide

6 October 2020

As COVID-19 continues to impact the global economy in unprecedented ways, companies that have had to scale back or shut down operations are bracing for what the next few months will bring, and what this means for their workforces. In this guide, we examine key considerations for employers looking to make permanent reductions in force across APAC.

---

#### Coronavirus Resource Center: Our global repository of insights and events

30 September 2020

A central repository for our reports and commentary on the legal and regulatory concerns arising from the pandemic.

---

#### New CFIUS regulations change mandatory filing requirements and increase the importance of US export controls

30 September 2020

The new rule modifies the criteria that trigger a mandatory filing with CFIUS, potentially subjecting more transactions to mandatory CFIUS review.

---

#### Philadelphia grows privacy capabilities with a new arrival

30 September 2020

Ronald Plesco, an internationally known information security and privacy lawyer, has joined our Philadelphia office.

---

#### The Pharmaceutical Corner

30 September 2020

In this inaugural column, we look at the implications of IPR and PGR proceedings in Hatch Waxman litigation.

---

#### Digital Therapeutics - evolution and entry into mainstream healthcare

18 September 2020

Research undertaken by DLA Piper's Life Sciences sector in conjunction with The Lawyer seeks to understand the current developments in the field of digital therapeutics, looking at key questions that need to be addressed if these products are to become mainstream components of health systems across the world.

---

#### Human rights compliance programmes in the Life Sciences sector

10 September 2020

The risk of adverse environmental, social or human rights impacts is one that Life Sciences businesses will be familiar with.

---

---

## Human rights compliance programmes: Why now?

10 September 2020

Businesses are increasingly required to identify and manage their involvement in adverse environmental and social impacts throughout their organisations and supply chains. Previously, drivers for developing human rights compliance programmes have included reputation risk and compliance with best practice and “soft law” standards.

---

## Russia Pharmaceuticals Sector Update - September 2020

3 September 2020

### [RUSSIA PHARMACEUTICALS SECTOR UPDATE](#)

Government approves regulations on granting organisations subsidies to partially reimburse expenses incurred in connection with product certification and homologation in foreign markets.

---

## Details of the second tranche of Hong Kong’s Employment Support Scheme released

24 August 2020

On 18 August 2020 the Hong Kong government announced details surrounding the second tranche of the Employment Support Scheme. While the majority of the rules surrounding the second tranche remain largely the same as the first tranche, there are new penalties for employers who have fallen foul of a number of nebulous terms.

---

## Release of exposure draft legislation for major reforms to Australia’s Foreign Investment Framework

10 August 2020

Many governments around the world have been strengthening their laws relating to foreign investment. Australia is no exception to this development and has just released proposed sweeping reforms to its foreign investment regime. In this article, we provide a high level overview of the key proposed amendments and our thoughts on how some of those proposals are likely to affect foreign investment into Australia.

---

## Vlog series: How to raise equity capital during the Coronavirus pandemic (UK)

4 August 2020

The first half of 2020 has seen an unprecedented volume of activity by companies raising capital through follow-on equity offerings on the London Stock Exchange in response to the Coronavirus pandemic. There have been over 140 equity issues on the London Stock Exchange’s main market or AIM since 20 March 2020 raising more than GBP14 billion.

---

## Hong Kong Government increases statutory entitlement for maternity leave

16 July 2020

On 10 October 2018, the Chief Executive stated in her policy address that the government proposed to increase the statutory maternity leave entitlement from ten to 14 weeks.

---

## Israel Group News July 2020

8 July 2020

### ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

---

## The legal challenges facing the vaping industry in the EU/UK and the US: An overview and a look ahead

7 July 2020

Notes as the industry matures.

---

## Russia Pharmaceuticals Sector Update - July 2020

7 July 2020

### RUSSIA PHARMACEUTICALS SECTOR UPDATE

On 17 March 2020 the Russian President signed an Order that allowed the distance sale of over-the-counter medicines. However, at that time, such sales were conditioned on federal legislation being adopted and the Russian Government outlining further mechanisms for such sales.

---

## Clinical trials during the COVID-19 pandemic: A global guide

2 July 2020

The consequences of the COVID-19 pandemic continue to develop dynamically. Some countries are beginning to ease lockdown measures, whilst others retain or even impose new restrictions. The situation continues to impact the ability to conduct clinical trials on a global scale. Pharmaceutical companies need to address even more challenges to ensure the continuity of trials on human medicines.

---

## A go-to firm for defending patent cases

30 June 2020

Recognition from *Law360*

---

## Atlanta expands privacy capabilities

30 June 2020

Lael Bellamy's arrival bolsters our data protection, privacy and security capabilities throughout the firm.

---

## Changes to Hong Kong anti-discrimination legislation

30 June 2020

Anti-discrimination laws in Hong Kong have undergone a series of changes over the past few years.

---

## **Hatch-Waxman Litigation 101: The Orange Book and the Paragraph IV Notice Letter**

30 June 2020

A few of the key issues that must be addressed before a Hatch-Waxman suit is filed.

---

## **Intellectual property rights are a renewed focus as the world looks beyond a global viral outbreak**

30 June 2020

A few key IP-related considerations for companies, whether they are seeking to expand into new markets or looking to preserve their place in an existing market.

---

## **Northern California bolsters telecom and regulatory practice**

30 June 2020

Regulatory and telecom attorney Kristin Jacobson has joined our Northern California office in Sacramento.

---

## **Washington, DC grows technology capabilities with two new arrivals**

30 June 2020

Marius Domokos and Justin Ilhwan Park have joined our Washington, DC practice.

---

## **First emerging technologies identified and controlled for export in the EAR**

26 June 2020

The designation also makes these a "critical technology," giving CFIUS jurisdiction over foreign investments in US businesses that engage with these items.

---

## **Therapies for COVID-19: Two major developments**

25 June 2020

The developments, one negative and one positive, involve widely available medications.

---

## **CFIUS encourages public to provide tips and referrals**

24 June 2020

The new webpage encourages tips and referrals about non-notified deals, violations of CFIUS mitigation measures, and other matters that raise national security risk.

---

## **Dublin office anniversary**

19 June 2020

Our people in the Irish practice are celebrating our first anniversary and the substantial growth that has been achieved in just 12 months.

---

## **Business protection: An Interactive guide**

18 June 2020

Global companies are at risk of their data and confidential information being leaked to competitors, especially when key employees leave. Protecting the integrity of new formulations and trade secrets is crucial, particularly for life sciences companies, to holding a competitive advantage and building success.

---

### **Australia tightens rules on foreign investment**

17 June 2020

In this article we summarise the tax-related developments from early June 2020, as Australia takes a more stringent approach towards compliance procedures involving foreign investments.

---

### **Preparing for global class actions arising from COVID-19**

28 May 2020

The risk to companies of global and cross-border class action and collective redress proceedings is rising.

---

### **Chinese and other emerging market companies listed in the US face increased scrutiny from Congress and Nasdaq**

27 May 2020

Within a span of two days, the US Senate, House and Nasdaq each took steps to safeguard investors in the US capital markets.

---

### **PFAS: in California, regulators put cleanup levels on hold, but announce major data hunt**

7 MAR 2019

This data hunt will affect thousands of facilities, drinking water systems and private drinking water well owners.

---

### **Intellectual Property and Technology News (United States), Issue 23, Q3 2014**

10 SEP 2014

#### **INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS**

Our Intellectual Property and Technology News reports on worldwide developments in IP and technology law, offering perspectives, analysis and visionary ideas.

---

### **Distributing patent rights between affiliates: guidelines to support enforcement rights around the world**

16 NOV 2015

Considering a few issues at the outset when rights are distributed between Parent and Affiliate (or between multiple affiliates) may avoid difficulties in the future when a company wants to enforce patent rights.

---

## **EVENTS**

### **Previous**

## **UPC: What should in-house teams be doing now?**

9 May 2022  
10:00 AM - 11:00 AM ET  
3:00 PM - 4:00 PM BST

---

## **Using AI to monitor your compliance risks**

31 March 2022  
Webinar

---

## **International Women's Day**

10 March 2022  
Webinar

---

## **Beyond Politics: The Person Behind the Policies**

16 February 2022  
Webinar

---

## **Embracing Digital Evolution**

15 September 2021  
Webinar

---

## **The societal, medical and economic consequences of the global pandemic and the lessons we can learn**

22 March 2021  
Webinar

---

## **EDPB recommendations for safeguarding data transfers after Schrems II**

19 November 2020  
Webinar

---

## **COVID-19: Present and future**

14 July 2020  
Webinar

---

## **NEWS**

---

## **DLA Piper advises Philip Morris International Inc. on USD16 billion recommended cash offer for Swedish Match**

12 May 2022

DLA Piper, as International Counsel, is advising Philip Morris Holland Holdings B.V., an Affiliate of Philip Morris International Inc. (PMI), on its USD16 billion recommended public offer to the shareholders of Swedish Match AB (Swedish Match), a public limited company with shares listed on Nasdaq Stockholm.

---

## **DLA Piper advises Linus Health on its acquisition of Kinesis Health Technologies**

6 April 2022

DLA Piper has advised Boston-based digital health company Linus Health on its acquisition of Kinesis Health Technologies, a Dublin-based leader in physical function assessment for older adults.

---

## **DLA Piper advises AOC as anchor shareholder of Formycon on acquisition of biosimilar assets**

31 March 2022

DLA Piper has advised Active Ownership Capital in connection with Formycon AG's acquisition of the biosimilar candidates FYB201 and FYB202 from ATHOS Group.

---

## **DLA Piper strengthens its litigation and international arbitration practice with partner Dr Marc Jacob**

16 March 2022

DLA Piper will strengthen its Litigation & Regulatory practice group with the appointment of Marc Jacob as a new partner in the Frankfurt office, effective 1 April 2022. He joins DLA Piper from Shearman & Sterling, where he practised litigation and international arbitration since 2013.

---

## **DLA Piper support Leafy Tunnel on Europe's first cannabis and psychedelics fund launch**

31 January 2022

DLA Piper Cannabis practice has advised Leafy Tunnel on the first closing of its Guernsey-based fund, established to invest in both medicinal cannabis and psychedelic companies; the first of its type in Europe.

---

## **DLA Piper advises Breffi on RUB750m investment from Elbrus Capital**

13 January 2022

DLA Piper has advised Breffi, a Russian omnichannel pharmaceutical marketing company, on a RUB750 million investment from Elbrus Capital, a Russia and CIS-focused private equity firm.

---

## **DLA Piper advises Russia's healthcare platform NaPopravku on USD5m investment round**

15 December 2021

DLA Piper has advised NaPopravku, a Russian online appointment service for clinics and doctors, on its USD5 million investment round led by Swedish investment company VNV Global, Russian investment holding Avenir and Malaysia's JobStreet.com founder Mark Chang.

---

### **DLA Piper advises Tentamus Group on investment in Lambda Científica and Actitum in Mexico**

6 September 2021

DLA Piper has advised Tentamus Group on an investment in Lambda Científica, S.A. de C.V. (Lambda) and Actitum MDC, S. de R.L. de C.V. (Actitum), leading analytical laboratories in the pharmaceutical sector in Mexico.

---

### **DLA Piper advises BestDoctor on USD26m Series B investment round**

14 July 2021

DLA Piper has advised BestDoctor, which is creating Russia's first health management system based on hi-tech medical insurance services, on the USD26 million Series B investment round.

---

### **DLA Piper advises HUTCHMED on its Hong Kong IPO**

8 July 2021

DLA Piper is advising global biopharmaceutical company HUTCHMED on its Hong Kong public offering. This will be the third listing for the company, following its first on London's AIM exchange and then NASDAQ in the US.

---

### **DLA Piper advises Poland's Copernicus on its sale to Nemera**

29 October 2020

DLA Piper has advised Copernicus, regarded as one of the most valued innovative companies in the Polish health sector, and its founders on its sale to Nemera, a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries.

---

### **DLA Piper advises VNV Global on c. USD2 million investment in Russia's healthcare platform NaPopravku**

23 September 2020

DLA Piper has advised VNV Global, a Swedish investment company, on its circa USD2 million investment (jointly with other investors) in NaPopravku, a Russian online appointment service for clinics and doctors, to develop a mobile application and expand into the regions.

---

### **DLA Piper advises BestDoctor on USD4.5 million investment round**

24 July 2020

DLA Piper has advised BestDoctor, a Russian medical insurance startup, on its US\$4.5 million investment round from a group of private investors led by Target Global, AddVenture and LVL1.

---

### **DLA Piper advises Dechra Pharmaceuticals on GBP133.4m share placing**

5 June 2020

DLA Piper has advised FTSE 250 veterinary pharmaceuticals business Dechra Pharmaceuticals (Dechra) on the placing of 5,1 million new

ordinary shares raising GBP133.4 million.

---

## DLA Piper advises Ping An on investment in Berlin health start-up Plusdental

29 May 2020

DLA Piper has advised Hong Kong based Ping An Global Voyager Fund (Global Voyager Fund) on an investment in the Berlin based health start-up Plusdental in a EUR32 million financing round.

---

## In Russia

---

Our international team of lawyers, consisting of Russian, English and US qualified lawyers, are experienced in a wide range of business transactions, including franchising, brand development, life sciences, pharmaceuticals and related matters. We advise international and local pharmaceutical companies on issues related to Russian regulatory framework for manufacturing, circulation and pricing of pharmaceuticals. We also offer advice on various aspects relating to compliance with regulatory requirements for importation and distribution of medical products and medical devices, and assist clients in the licensing of medical product manufacturing technology. Finally, we also extensively advise international and local pharmaceutical companies in various forms of M&A and private equity transactions.

Sophisticated biotechnology and pharmaceutical clients want and need their lawyers to understand their business, anticipate legal problems, know how others in the industry are addressing emerging issues, know what regulators and tax professionals think, and be able to provide timely answers. It takes extensive industry involvement to provide this level of service. This is why DLA Piper is the logical choice for life sciences companies seeking a strategic legal partner in Russia.

### EXPERIENCE

- Advising a major Japanese pharmaceutical company in a competitive sale process for the acquisition of over-the-counter and food supplement brands in Russia worth US\$ 1 billion, including due diligence and full transaction support.
- Advising a major Japanese pharmaceutical company in a competitive sale process for the acquisition of over-the-counter brands in the CIS worth US\$ 500 million, including due diligence and full transaction support.
- Advising a large Hungarian pharmaceutical company in a competitive sale process for the acquisition of a US\$ 100 million asset in Russia, including due diligence and full transaction support.
- Advising a large Russian group of companies on the sale of the over-the-counter pharmaceuticals company in Russia to an international pharmaceuticals company headquartered in Canada.
- Advising a Russian company and its group involved in organization of clinical trials (medical testing at preregistration phase) and operating in various jurisdictions across Eastern Europe and in the US, on various structuring issues in connection with the company's contemplated expansion to Western European markets, including due diligence.
- Acting for a German multinational chemical and pharmaceutical company in reorganisation and restructuring in relation to the merger of the Russian subsidiaries of Bayer and Schering-Plough (as part of the global Bayer-Schering merger), including advice on both general corporate and tax issues, and legal and tax due diligence of draft agreements regarding the Russian distribution campaign.
- Providing legal assistance to a large US life sciences company with regard to a full pre-acquisition due diligence of a St Petersburg-based pharmaceutical company.
- Advising a leading Italian life sciences multinational company on the restructuring of its US\$ 90 million IP assets acquired as part of the acquisition of a Russian bio-pharma target company, including extensive tax and IP advice specifically with respect to acquiring and restructuring all the license operations and intellectual property in Russia for the Italian group, involving the structuring of several patents, industrial designs and over 100 trademarks use for drugs and biologically active additions.
- Advising a US based global healthcare company on a joint venture project related to import and distribution of pharmaceuticals in Russia, including advice on Russian pricing regulations.
- Acting for a leading Norwegian engineering and construction company working across a number of industries, including pharmaceuticals, in its acquisition of a Russian engineering bureau. The mandate included significant regulatory support in addition to the M&A work.

- Advising a Swiss based global healthcare company on setting up a EUR 80 million greenfield project in Special Economic Zone (SEZ) Novovorlovskaya, St Petersburg, including registration of a legal entity in St Petersburg, analysis of the SEZ agreement required for granting Novartis SEZ resident status, conducting due diligence in relation to the land plot in order to detect key risks.
- Advising a leading global biopharma company in relation to general employment law matters, including reorganisation.
- Advising a leading international medical technology company and developer of hearing implants system, in the planning, structuring, negotiation and document preparation for the completion of a know-how license and distribution relationship for the manufacture and sale of medical devices in Russia.
- Representing a major world-wide pharmaceutical company in relation to the stoppage of unauthorized use of five domain names by a third party and the related settlement agreement.
- Representing a major German personal-care company in a landmark domain name cyber-squatting case.
- Advising a number of clients on regulatory and practical aspects of structuring clinical trials.

## Sustainability and ESG

---

Sustainability and resilience are core business issues in the life sciences sector, given the sector's central role in addressing systemic global challenges including pandemics, access to medicine, and fundamental human rights. Although the specific factors from a sustainability, environmental, social and governance (SESG) perspective in the life science industry differ from those of other industries, creating new and sustainable value in the life science space will depend upon how companies address relevant SESG risks. Boards must actively identify such SESG risks and ensure that they are efficiently mitigated in order for their companies to avoid pitfalls and ensure compliance with evolving regulation around the globe – and also to maintain their competitive position and profitability.

On the basis of our experience in the sector, we believe the following sustainability-related themes to be the core SESG issues that will continue to affect life science businesses:

- **Access and affordability:** Addressing unmet healthcare needs, increasing access to affordable essential medicines and strengthening health systems around the world are all fundamental to social and economic progress. The coronavirus disease 2019 (COVID-19) has further highlighted the importance of the life sciences sector in addressing these challenges. Against this background, international life science business will need to engage in discussions about and develop strategies addressing these issues across the world, particularly with regard to improving the situation in lesser developed countries.
- **Supply chain compliance:** Many governments and regulators around the world are implementing tighter rules on supply chain compliance. To retain their license to operate, life sciences companies must adhere to an evolving set of global laws and regulations. Furthermore, transparency requirements, as well as responsibility and liability for global suppliers are increasing. This ongoing regulatory shift, and the increased likelihood of litigation which goes with it, will have a significant impact on the global life sciences industry. This is because supply chains are often particularly lengthy and complex and influenced by many different internal and external factors that are hard to monitor and control.
- **Product safety and quality:** Fake or substandard medicines lead to hundreds of thousands of deaths each year. Drug safety, along with protecting health consumers from counterfeit medicines and drug diversion, are integral to ensuring public health and maintaining trust and confidence in the life sciences sector. Consequently, life science companies will need to put increasing focus on ensuring product safety as well as maintaining secure distribution channels to patients.
- **Business ethics:** There is increasing stakeholder attention, including from regulators and policymakers and also from providers of capital, on transparency and ethics in business dealings with healthcare providers and medical practitioners for the sale and use of products, as well as in relation to lobbying and advocacy activities. The way in which businesses respond to these expectations can have a direct impact upon their reputation, their cost of capital and ultimately upon their license to operate.
- **Transparency and access in clinical trials:** Stakeholders increasingly expect transparency in clinical trials and wider access to trial data for scientific exchange and research. There is a bright spotlight on participant safety and privacy. Businesses are demanding more effective information sharing to enable informed decision-making and consent, along with post-trial access to results. Technology and collaborative partnerships with patient and health worker groups enable wider representative demographic populations to participate in clinical trials.
- **Sustainable sourcing, product lifecycles and a circular economy:** Markets demand greater visibility across product lifecycles, businesses make commitments to net-zero decarbonisation and business model innovation is driven by circular economy concepts. Underpinned by an increasingly complex transnational regulatory landscape, these developments are changing the way raw materials are sourced; how products are designed, manufactured, packaged, sold, reused or recycled; how waste and hazardous material is treated; and how wider environmental and social impacts relating to issues like emissions, plastics, water use, biodiversity loss, labour

conditions and community impacts are managed.

- **Net-zero decarbonisation and optimisation of processes:** In striving to decarbonise the economy, businesses are implementing commitments to Science Based Targets, increasing energy efficiency and reducing carbon output, decreasing dependency on fossil fuels and increasing the use of renewables. The implementation of these initiatives is creating operational efficiencies, optimising the drug manufacturing, packaging and distribution process and reducing costs across the sector.

---

To discuss the implications of these issues for your business, please contact our ESG leaders.